ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product marketing and sales across small biotech start-ups and multi-national pharmaceutical companies.
“I am pleased to welcome Alex to the ERYTECH team at this exciting juncture,” said Gil Beyen, Chairman and CEO of ERYTECH. “His extensive experience in market access and commercial product launches will provide an invaluable foundation for commercial product preparedness and lay the groundwork for commercial success of our late-stage product candidates worldwide, with initial focus on the United States.”
Prior to joining ERYTECH, Mr. Dusek served as the Vice President of Commercial Strategy at Argos Therapeutics, a publicly traded immuno-oncology company, where his work included pre-launch planning for the commercial distribution of an advanced cell therapy product. Before Argos, Mr. Dusek led the global brand strategy at Bayer HealthCare Pharmaceuticals for the launch of a first-in-class, rare-disease agent, Adempas (riociguat). He was the first marketing employee at United Therapeutics hired to build the marketing infrastructure and grow the pulmonary hypertension franchise. Mr. Dusek earned a B.A. in Linguistics from the College of William and Mary, completed a post-baccalaureate pre-medical program at Columbia University, and received his M.B.A from the University of North Carolina, Kenan-Flagler Business School.
“ERYTECH is the leader in red blood cell-based cancer therapeutics,” stated Mr. Dusek. “I’m excited to join a company with advanced clinical programs and a platform that offers the potential promise to treat patients suffering from many different serious diseases. I look forward to utilizing my broad product launch experience and assisting the team in the transformation of ERYTECH from a development company to a commercially successful operation.”
Mr. Dusek will be based in the United States, joining ERYTECH’s growing team in Cambridge, Massachusetts.
About ERYTECH: www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
This press release contains forward-looking statements, forecasts and estimates. These statements, forecasts and estimates may be identified by the use of words such as “anticipate,” “expect,” “will,” “believe,” “continue,” “enable” and other similar terms and phrases. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation statements regarding the potential of ERYTECH’s product pipeline, its clinical development and regulatory plans of eryaspase. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH’s control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2017 Document de Référence filed with the AMF in April 2018 and in the Company’s Annual Report on Form 20-F filed with the SEC on April 24, 2018 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Director Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
+33 1 44 71 98 52
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Andersen Global’s Middle East Expansion Continues with Solutions Bridge in Kuwait24.5.2018 13:30 | Pressemelding
Solutions Bridge, an Accounting and Corporate Secretarial Services firm in Kuwait City, has signed a Collaboration Agreement with Andersen Global. The addition of a location in Kuwait demonstrates Andersen Global’s growth in the Middle East, which is a significant market for the organization. “Having a strong practice in Kuwait is important to our regional success and this is an extraordinary opportunity to continue providing best-in-class services globally,” commented Mark Vorsatz, Global Chairman and Andersen Tax LLC CEO. “There are many changes in the Middle East currently and the development of tax laws is a major factor in the region. The addition of Solutions Bridge, one of the largest accounting firms in Kuwait, positions us for continued opportunities for expansion.” Formed by former professionals of Andersen in Kuwait, Solutions Bridge is led by Partner Fouad Al Hourani. The firm provides accounting and corporate secretarial services for both individuals and corporations in a
Workiva Signs OEM Agreement with SAP to Offer SAP® Cloud Platform Integration with the Workiva Wdesk Platform24.5.2018 13:00 | Pressemelding
Workiva (NYSE:WK), a leader in cloud-based data collaboration, reporting and compliance solutions, today announced it has signed an original equipment manufacturer (OEM) agreement with SAP (NYSE:SAP). Through this agreement, Workiva is partnering with SAP to provide a first-party integration with the Wdesk platform using the SAP® Cloud Platform Integration service. The bundled solutions are expected to provide customers with powerful linking, auditability and control features. “Today’s announcement demonstrates that Workiva and SAP are committed to providing customers with a rich integration experience,” said Matt Rizai, chairman and CEO of Workiva. “Through our OEM partnership, we will help customers all over the world improve the value of their business data.” After users integrate their SAP business data directly into the Wdesk platform, they can benefit from the full capabilities of Wdesk, including synchronized data, dynamic commentary, controlled collaboration, granular permissio
M-Brain Appoints New CEO24.5.2018 12:25 | Pressemelding
M-Brain, a global leader in market and media intelligence solutions, has appointed Christian Cedercreutz Chief Executive Officer as of 13.8.2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005676/en/ M-Brain, a global leader in market and media intelligence solutions, has appointed Christian Cedercreutz Chief Executive Officer as of 13.8.2018. (Photo: Business Wire) Christian holds a Master of Economics degree from Hanken School of Economics in Helsinki. His career has been built with IBM over the past 20 years, in which he has held various management positions in five different European countries. Christian brings strong consultative selling experience and has over the years worked across the IBM Corporation in roles such as leading global client relationships, and leading SW and HW technology businesses in Finland. His most recent role has been to lead the cognitive SW solutions (Watson) business in Finland. Simu
IBIN Introduced into Billion Dollar Blockchain Market by Hybrid Stock Exchange24.5.2018 12:13 | Pressemelding
Hybrid Stock Exchange, a blockchain based trading platform using the released IBIN as a blockshare identifier, are all set to adopt innovative features to sustain the needs of the ever growing industry. Watch the HYBSE trailer here: http://www.hybse.com The International Securities Identification Number (ISIN) is a 12 character code that uniquely identifies a specific security, such as stocks, and is the most popular global securities identifier. With the pre-registration for issuers and users opened, the DIM Ecosystem introduces the International Blockshare Identification Number (IBIN), a 13 digit, unique serial number used by a company for listing on the Hybrid Stock Exchange or other Blockchain Exchanges. Tradable securities on HYBSE currently include Cryptonized equity, Cryptocurrencies, Exchange-traded commodities, index, and more. Any issuers are able to apply for their IBIN at no charge. This limited time offer is available until August 31, 2018 or for the first 75 companies tha
IDEMIA Will Present Its Q1 2018 Financial Results to Investors on May 25, 201824.5.2018 11:33 | Pressemelding
IDEMIA, the world leader in Augmented Identity, today announced that it will present its Q1 2018 financial results to investors on Friday May 25, 2018. Didier Lamouche (CEO) and Frédéric Beylier (COO) will be presenting these financial results and taking questions the same day at 1pm CET (12pm London Time / 7am New York Time). For more information, please refer to our website: http://investors.oberthur.com About IDEMIA OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients fro
eLichens Provides Open Access to Its Real-Time and Air Quality Forecast Data to Facilitate the Emergence of Services to Citizens24.5.2018 09:37 | Pressemelding
Designer of patented gas sensors and the first comprehensive air quality analysis and prediction platform, eLichens today announced it is providing open data access to its hyper local real-time and air quality forecast data for the city of Grenoble. This will facilitate the development of services to communities, service industries and citizens concerned about the quality of the air they breathe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005521/en/ eLichens has developed a complete platform for smart city applications, based on its dense network of air quality stations and cloud models to measure and predict air quality at a very high precision. https://www.elichens.com/smart-city The high resolution mapping of Grenoble's air pollution published by eLichens is produced from the integration of various parameters: topographic data, real-time road traffic, meteorology of the city of Grenoble, advanced gas dispersion